ArticleTurkish journal of urology2021
Is the use of ultra-low insufflation pressure safe and feasible in robot assisted radical prostatectomy.
Article in Turkish journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.
- Low pressure pneumoperitoneum in robotic surgery: a systematic review and meta-analysis.Journal of robotic surgery · 2026Pooled it
- Lower vs standard pressure pneumoperitoneum in robotic-assisted radical prostatectomy: a systematic review and meta-analysis.Journal of robotic surgery · 2023Pooled it
- Anesthesiological and surgical perspectives on using 8 mmHg versus 12 mmHg pneumoperitoneum pressures during robotic radical prostatectomy: Results of a prospective randomized study.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2024Trial
- The Impact of intra-abdominal Pressure on Perioperative Outcomes in Robotic-Assisted Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Journal of oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCurrent innovations in minimally invasive surgery include using ultra-low insufflation pressure with the aim of improving peri-operative and short-term clinical outcomes. Despite an exponential increase in the use of robotic technology, there remains limited literature supporting the use of ultra-low pressure during robotic surgery. We performed a feasibility study of ultra-low-pressure robot-assisted laparoscopic radical prostatectomy (RARP). MATERIAL AND
methodsProspective data related to standard pressure (15 mm Hg) RARP (Group 1) and ultra-low-pressure (6 mm Hg) RARP (Group 2) were collected and compared to assess the peri-operative and short-term outcomes.
resultsOutcome data of 112 consecutive patients (56 in each group) were collected. Mean age, pre-operative prostate specific antigen, body mass index, and performance status were similar in both groups. Mean console time was shorter in ultra-low-pressure RARP group (125 minutes) than in standard pressure RARP group (138 minutes) (p=0.016). Furthermore, there was no significant difference in console time or estimated blood loss between these 2 groups for patients with RARP and lymph node dissection. No patients from either group required conversion to an open procedure or received a peri-operative blood transfusion. None of the patients in either group developed post-operative complications or needed readmission.
conclusionOur study has demonstrated that ultra-low-pressure RARP is a practical and safe option, and it supports the routine practice of ultra-low-pressure RARP with slow adaptation in other complex robotic surgeries, such as robotic cystectomy for bladder cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.